Table 1.
Clinical characteristics of subjects involved in this study.
| Patient | Sex | Age | RT‐PCR NP swab status | CT‐scan signs of COVID‐19 | SARS‐CoV‐2 in stool (copies mg−1) | Δ RT‐PCR NP swab and stool (days) | PlasmaCRP (mg L−1) | Severity of pulmonary signs | Comorbidities | Antibiotic treatment |
|---|---|---|---|---|---|---|---|---|---|---|
| C01P001 | M | 99 | (+) | No | 3.6E + 04 | 34 | 68.9 | No sign | 1, 2, 5 | Amoxicillin/Clavulanate |
| C01P002 | M | 66 | (−) | Yes | (−) | 5 | 64.5 | Mild | 2, 4 | |
| C01P003 | M | 79 | (+) | Yes | 1.4E + 03 | 8 | 32.4 | Moderate | 1, 6 | 3rd gen Cephalosporins, Metronidazole |
| C01P004 | F | 67 | (+) | Yes | (−) | 17 | 3.2 | Moderate | 0 | |
| C01P005 | F | 91 | (+) | No | (−) | 1 | 7.4 | No sign | 1, 2 | |
| C01P006 | F | 54 | (+) | Yes | (−) | 14 | 30.1 | Moderate | 0 | Vancomycin, Cephazolin Linezolid |
| C01P007 | F | 88 | (+) | No | 1.4E + 01 | 1 | 2.4 | No sign | 1, 2 | Amoxicillin/Clavulanate |
| C01P008 | M | 60 | (+) | Yes | (−) | 20 | 1.2 | Severe | 1 | |
| C01P009 | F | 83 | (+) | No | (−) | 4 | 12.3 | No sign | 0 | |
| C01P010 | F | 92 | (−) | No | (−) | – | 103.1 | No sign | 1, 2 | Amoxicillin/Clavulanate |
| C01P011 | M | 85 | (+) | No | (−) | 7 | 4.2 | No sign | 1, 2 | |
| C01P012 | F | 83 | (+) | Yes | (−) | 9 | 3.9 | Mild | 1, 2, 3, 5 | |
| C01P013 | F | 47 | (+) | Yes | (−) | 1 | 15.6 | Moderate | 0 | |
| C01P014 | M | 63 | (+) | Yes | (−) | 21 | 1.9 | Severe | 0 | |
| C01P015 | F | 54 | (−) | Yes | (−) | 8 | 7.6 | severe | 4 | |
| C01P016 | M | 82 | (+) | No | 6.8 | 5 | 48.9 | No sign | 1, 6 | |
| C01P017 | M | 61 | (−) | No | (−) | – | 23.3 | No sign | 2, 6 | |
| C01P018 | M | 48 | (+) | Yes | (−) | 11 | 65.6 | Mild | 4 | |
| C01P019 | F | 77 | (+) | No | (−) | 15 | 2.2 | Mild | 1 | |
| C01P020 | M | 96 | (+) | No | (−) | 3 | 37.9 | No sign | 1, 4 | |
| C01P021 | F | 56 | (+) | Yes | (−) | 6 | 30 | Moderate | 0 | |
| C01P022 | M | 76 | (+) | Yes | 2.5E + 01 | 10 | 251.3 | Severe | 1, 2 | |
| C01P023 | F | 82 | (−) | No | (−) | 3 | 70.9 | Mild | 1, 2, 3, 5 | Ceftriaxone |
| C01P024 | M | 60 | (−) | Yes | (−) | 30 | 3.9 | Severe | 0 | |
| C01P025 | M | 75 | (−) | No | (−) | – | 37.9 | No sign | 1, 2 | |
| C01P027 | M | 79 | (−) | No | (−) | – | 13 | No sign | 1, 6 | Trimethoprim/Sulfamethoxazole |
| C01P028 | F | 40 | (−) | Yes | (−) | – | 25.8 | Mild | 0 | |
| C01P029 | F | 84 | (+) | No | 3.6E + 04 | 4 | 133.7 | No sign | 1, 2, 4 | Amikin Imipenem/Cilastatin |
| C01P030 | F | 78 | (−) | Yes | (−) | – | 2.3 | No sign | 2, 4 | Cefotaxime, Spiramycin |
| C01P031 | F | 76 | (−) | No | (−) | – | 32.4 | No sign | 1, 3 | |
| C01P032 | M | 69 | (−) | Yes | (−) | 4 | 8 | Severe | 2 | Cefotaxime, Daptomycin |
| C01P033 | F | 95 | (+) | Yes | 9.6E − 01 | 2 | 14.1 | Mild | 1, 2 | |
| C01P035 | M | 34 | (+) | No | 1.5 | 3 | 1.6 | No sign | 4 | |
| C01P036 | F | 58 | (+) | Yes | 1.0E + 01 | – | 66.5 | Moderate | 2 | |
| C01P037 | M | 87 | (+) | No | (−) | 6 | 38.5 | No sign | 1, 2 | |
| C01P038 | M | 96 | (+) | No | (−) | 1 | 5 | No sign | 1, 2 | |
| C01P039 | F | 68 | (+) | Yes | (−) | 8 | 21.2 | Moderate | 2 | |
| C01P040 | F | 79 | (+) | No | (−) | 9 | 20.8 | Moderate | 1, 3 | Amoxicillin/Clavulanate |
| C01P041 | M | 91 | (+) | No | 6.9E + 01 | 3 | 85 | No sign | 1 |
Comorbidities: (0) Any, (1) Age > 70, (2) Antecedents of cardiovascular disease, (3) Uncontrolled diabetes with complications, (4) Chronic respiratory disease, (5) Chronic renal disease, (6) Cancer, (7) Obesity.